Get the Stockscreener App
42.63
2.89%
-1.27
Definium Therapeutics Inc stock is traded at $42.63, with a volume of 1.70M.
It is down -2.89% in the last 24 hours and down -7.29% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$43.90
Open:
$43
24h Volume:
1.70M
Relative Volume:
0.59
Market Cap:
$5.73B
Revenue:
-
Net Income/Loss:
$-237.54M
P/E Ratio:
-17.03
EPS:
-2.5033
Net Cash Flow:
$-145.05M
1W Performance:
-7.61%
1M Performance:
-7.29%
6M Performance:
+170.67%
1Y Performance:
+0.00%
1-Day Range:
$42.01
$43.74
1-Week Range:
$40.62
$47.55
52-Week Range:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
42.63 | 5.75B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo
Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance
DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - MarketBeat
DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance
DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - MarketBeat
DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - MarketBeat
Definium Phase III success with DT120 in anxiety - The Pharma Letter
Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - MarketBeat
Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Australia
Canaccord raises Definium Therapeutics price target on trial data - Investing.com
DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - MarketBeat
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha
DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus
Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - MarketBeat
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView
Definium Therapeutics (NASDAQ:DFTX) Shares Gap UpWhat's Next? - MarketBeat
Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium Therapeutics CEO Robert Barrow Acquires 375,000 Shares via Performance Share Units - Kalkine Media
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' - benzinga.com
Definium Therapeutics Announces Positive Phase 3 Voyage Topline Results for DT120 ODT - Kalkine Media
Definium Therapeutics (DFTX) Shares Surge After Positive Phase 3 Trial; Valuation Hinges on Future Growth - GuruFocus
Form 8K Definium Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Definium Therapeutics stock jumps 20% on Phase 3 trial results By Investing.com - Investing.com Canada
Definium Therapeutics (DFTX) awards 62,500 performance-based shares to Chief Commercial Officer - Stock Titan
Definium Therapeutics (DFTX) awards CEO 375,000 performance-based shares - Stock Titan
Definium Therapeutics (DFTX) CFO receives 62,500-share performance-based equity grant - Stock Titan
Definium Therapeutics (DFTX) CLO awarded 62,500 performance-based shares in PSU tranche - Stock Titan
Wondering what's happening in today's pre-market session? - ChartMill
Definium Therapeutics posts positive Phase 3 Voyage topline: DT120 ODT cuts HAM-A by 5.4 pts vs placebo - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com
Definium Therapeutics (Nasdaq: DFTX) reports positive DT120 GAD Phase 3 data - Stock Titan
Definium Therapeutics shares surge after positive Phase 3 anxiety trial results - Yahoo Finance
Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo - marketscreener.com
Definium Therapeutics stock jumps 20% on Phase 3 trial results - Investing.com
Definium reports positive phase 3 results for anxiety drug By Investing.com - Investing.com UK
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of Dt120 Odt in Generalized Anxiety Disorder - marketscreener.com
Research Analysts Set Expectations for DFTX Q3 Earnings - MarketBeat
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):